<?xml version='1.0' encoding='utf-8'?>
<document id="25393993"><sentence text="Efavirenz- but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a sub-dermal contraceptive implant."><entity charOffset="19-29" id="DDI-PubMed.25393993.s1.e0" text="nevirapine" /><entity charOffset="85-99" id="DDI-PubMed.25393993.s1.e1" text="levonorgestrel" /><pair ddi="false" e1="DDI-PubMed.25393993.s1.e0" e2="DDI-PubMed.25393993.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s1.e0" e2="DDI-PubMed.25393993.s1.e1" /></sentence><sentence text="Sub-dermal hormone implants, such as levonorgestrel (LNG), are a safe and desirable form of long-acting contraception, but their use among HIV-positive women on antiretroviral therapy (ART) may be compromised given the potential for a cytochrome P450 3A-mediated drug-drug interaction"><entity charOffset="37-51" id="DDI-PubMed.25393993.s2.e0" text="levonorgestrel" /><entity charOffset="53-56" id="DDI-PubMed.25393993.s2.e1" text="LNG" /><pair ddi="false" e1="DDI-PubMed.25393993.s2.e0" e2="DDI-PubMed.25393993.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s2.e0" e2="DDI-PubMed.25393993.s2.e1" /></sentence><sentence text=" Our study aimed to characterize the pharmacokinetics of LNG released from a sub-dermal implant over six months in HIV-positive Ugandan women on nevirapine (NVP)- or efavirenz (EFV)-based ART"><entity charOffset="145-155" id="DDI-PubMed.25393993.s3.e0" text="nevirapine" /><entity charOffset="166-175" id="DDI-PubMed.25393993.s3.e1" text="efavirenz" /><entity charOffset="177-180" id="DDI-PubMed.25393993.s3.e2" text="EFV" /><entity charOffset="57-59" id="DDI-PubMed.25393993.s3.e3" text="LNG" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e3" e2="DDI-PubMed.25393993.s3.e3" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e3" e2="DDI-PubMed.25393993.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e3" e2="DDI-PubMed.25393993.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e3" e2="DDI-PubMed.25393993.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e0" e2="DDI-PubMed.25393993.s3.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e0" e2="DDI-PubMed.25393993.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e0" e2="DDI-PubMed.25393993.s3.e2" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e1" e2="DDI-PubMed.25393993.s3.e1" /><pair ddi="false" e1="DDI-PubMed.25393993.s3.e1" e2="DDI-PubMed.25393993.s3.e2" /></sentence><sentence text="" /><sentence text="This non-randomized, parallel group study compared LNG pharmacokinetics between HIV-positive Ugandan women not yet eligible for ART (control group, n=18) and those on stable NVP- (n=20) or EFV- (n=20) based ART"><entity charOffset="51-53" id="DDI-PubMed.25393993.s5.e0" text="LNG" /><entity charOffset="189-191" id="DDI-PubMed.25393993.s5.e1" text="EFV" /><pair ddi="false" e1="DDI-PubMed.25393993.s5.e0" e2="DDI-PubMed.25393993.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s5.e0" e2="DDI-PubMed.25393993.s5.e1" /></sentence><sentence text=" The two-rod (75 mg/rod) LNG sub-dermal implant was inserted at study enrolment"><entity charOffset="25-27" id="DDI-PubMed.25393993.s6.e0" text="LNG" /></sentence><sentence text=" LNG sampling was obtained pre-implant and at weeks 1, 4, 12 and 24 post-insertion"><entity charOffset="1-3" id="DDI-PubMed.25393993.s7.e0" text="LNG" /></sentence><sentence text=" LNG concentrations were analyzed using a validated LC-MS/MS method, with an assay calibration range of 50-1500 pg/mL"><entity charOffset="1-3" id="DDI-PubMed.25393993.s8.e0" text="LNG" /></sentence><sentence text=" Safety monitoring, including a pregnancy test, was conducted at each study visit" /><sentence text="" /><sentence text="At enrolment, participants had a mean age of 31 years; CD4+ cell counts were similar between the control, NVP and EFV groups (758, 645 and 568 cells/mm(3), respectively; p=0"><entity charOffset="114-116" id="DDI-PubMed.25393993.s11.e0" text="EFV" /></sentence><sentence text="09); all women in the NVP and EFV groups had an undetectable HIV-RNA"><entity charOffset="30-32" id="DDI-PubMed.25393993.s12.e0" text="EFV" /></sentence><sentence text=" Women in the control group had a higher baseline body weight (73 kg) compared to those in the NVP (63 kg; p=0" /><sentence text="03) or EFV groups (60 kg; p&lt;0"><entity charOffset="7-9" id="DDI-PubMed.25393993.s14.e0" text="EFV" /></sentence><sentence text="01)" /><sentence text=" By linear regression, weight was a significant predictor of LNG concentrations (1 kg increase in weight=5 pg/mL decrease in LNG, p=0"><entity charOffset="61-63" id="DDI-PubMed.25393993.s16.e0" text="LNG" /><entity charOffset="125-127" id="DDI-PubMed.25393993.s16.e1" text="LNG" /><pair ddi="false" e1="DDI-PubMed.25393993.s16.e0" e2="DDI-PubMed.25393993.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s16.e0" e2="DDI-PubMed.25393993.s16.e1" /></sentence><sentence text="03)" /><sentence text=" LNG concentrations are reported in the table"><entity charOffset="1-3" id="DDI-PubMed.25393993.s18.e0" text="LNG" /></sentence><sentence text="" /><sentence text="Over a 24-week period, LNG concentrations were 40-54% lower in women on EFV-based ART, despite their having a significantly lower body weight, compared to those not on ART"><entity charOffset="23-25" id="DDI-PubMed.25393993.s20.e0" text="LNG" /><entity charOffset="72-74" id="DDI-PubMed.25393993.s20.e1" text="EFV" /><pair ddi="false" e1="DDI-PubMed.25393993.s20.e0" e2="DDI-PubMed.25393993.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s20.e0" e2="DDI-PubMed.25393993.s20.e1" /></sentence><sentence text=" In women on NVP-based ART, LNG concentrations were 32-39% higher than those observed in the control group, a difference partially explained by body weight"><entity charOffset="28-30" id="DDI-PubMed.25393993.s21.e0" text="LNG" /></sentence><sentence text=" These data confirm a significant drug interaction occurs between the LNG implant and EFV, adding to growing concern for reduced contraceptive efficacy with their combined use"><entity charOffset="70-72" id="DDI-PubMed.25393993.s22.e0" text="LNG" /><entity charOffset="86-88" id="DDI-PubMed.25393993.s22.e1" text="EFV" /><pair ddi="false" e1="DDI-PubMed.25393993.s22.e0" e2="DDI-PubMed.25393993.s22.e0" /><pair ddi="false" e1="DDI-PubMed.25393993.s22.e0" e2="DDI-PubMed.25393993.s22.e1" /></sentence><sentence text=" In contrast, these data support use of the LNG implant with NVP-based ART"><entity charOffset="44-46" id="DDI-PubMed.25393993.s23.e0" text="LNG" /></sentence><sentence text="" /></document>